...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cardiovascular therapeutics >Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-st elevation acute coronary syndromes undergoing early percutaneous coronary intervention
【24h】

Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-st elevation acute coronary syndromes undergoing early percutaneous coronary intervention

机译：标准剂量与半剂量替罗非班在接受早期经皮冠状动脉介入治疗的非增高急性冠脉综合征患者中的疗效和安全性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary: Introduction: To explore the optimal dosage of tirofiban associated with double benefits of efficacy and safety in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) undergoing early percutaneous coronary intervention (PCI). Aims: A total of 163 patients were included in this study (78 in SD group versus 85 in HD group). In SD (HD) group, tirofiban was administered intravenously with a bolus dose of 10 (5) μg/kg within 3 min and followed by continuous intravenous infusion of 0.15 (0.075) μg/kg/min for 48 h. Within 24 h on admission, patients underwent CAG or CAG+PCI. The angiographic results (initial TIMI, final TIMI/CTFC/TMPG) were evaluated. Platelet aggregation rate (PAR) was measured before and 2, 24, 48 h after bolus tirofiban. MACEs were evaluated at 7-day, 30-day, and 6-month follow-up. Bleeding was observed at 7 days. Results: The proportions of TIMI grade 3 seemed higher in SD group before and after PCI followed by a better myocardial perfusion, but not statistically different (P = 0.26/0.08). PAR was lower in SD group than that in HD group at 2 h after bolus tirofiban (P = 0.03). MACEs were not statistically different at 7, 30 day, and 6 month in two groups. The incidence of minor bleeding was significantly lower in HD group than that in SD group (8.2% vs. 20.5%, P = 0.04). The risk of bleeding would increase under the conditions of decreased PAR, increased dose of tirofiban and decreased CCr. Conclusion: Half-dose tirofiban was not inferior to standard-dose in efficacy, what is more, half-dose tirofiban showed a better safety characteristic of lower bleeding risk. Therefore, half-dose tirofiban is recommended to patients with NSTE-ACS undergoing early PCI.
机译：摘要：简介：探讨替罗非班的最佳剂量与接受早期经皮冠状动脉介入治疗（PCI）的非ST段抬高急性冠状动脉综合征（NSTE-ACS）患者的疗效和安全性双重益处。目的：本研究共纳入163例患者（SD组78例，HD组85例）。在SD（HD）组中，替罗非班在3分钟内以10（5）μg/ kg的推注剂量静脉内给药，然后连续0.15（0.075）μg/ kg / min静脉输注48小时。入院后24小时内，患者接受CAG或CAG + PCI治疗。评估了血管造影结果（初始TIMI，最终TIMI / CTFC / TMPG）。在替罗非班推注之前，2、24、48 h测量血小板凝集率（PAR）。在7天，30天和6个月的随访中评估了MACE。在第7天观察到出血。结果：SD组PCI前后TIMI 3级的比例似乎较高，随后心肌灌注更好，但无统计学差异（P = 0.26 / 0.08）。替罗非班推注后2 h，SD组的PAR低于HD组（P = 0.03）。两组在7、30天和6个月时，MACE差异无统计学意义。 HD组轻微出血的发生率显着低于SD组（8.2％vs. 20.5％，P = 0.04）。在PAR降低，替罗非班剂量增加和CCr降低的情况下，出血的风险将增加。结论：半剂量替罗非班的疗效不逊于标准剂量，而且半剂量替罗非班显示出较低的出血风险，具有较好的安全性。因此，对于接受早期PCI的NSTE-ACS患者，建议使用半剂量替罗非班。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号